Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2022

View Archived Issues

New xenograft model of sporadic inclusion body myositis shows no role of T-cell depletion

Novel mutations in the FGG gene tied to thrombosis and dysfibrinogenemia

ETV6 and FYB1 rare genetic mutations tied to inherited thrombocytopenia

Disruption of tumor N-glycosylation improves the efficacy of CAR T-cell therapy in solid carcinomas

A mitochondrial genetic signature characterizes the most aggressive liver cancers in mice and humans

New kinetic model for a minimal cell helps to quantitatively understand the principles of life

Drug-free nanoparticle scavenges cell-free DNA and ROS to treat inflammatory bowel disease

Tactogen patents 5-HT1B receptor agonists and MAO-A inhibitors

Selenium mediates neurogenesis after hippocampal injury

Aligos Therapeutics discloses new THR agonists

VelosBio identifies new anti-ROR1 ADCs

Klotho Therapeutics synthesizes novel compounds for hypertension

Bristol Myers Squibb presents new FPR agonists

Fibrinogen as marker of joint health in patients with severe hemophilia

eTheRNA and Merck KGaA sign research agreement to assess mRNA technology for therapeutic vaccination

Parkinson's UK and Domainex collaborate to target neuroinflammation to slow Parkinson's disease

Mindset to initiate proof-of-concept preclinical studies on Family 3 compounds for cognitive benefit

Ascletis reports preclinical data on ASC-10 and ASC-10-A against SARS-CoV-2 variants

Dyve and Moffitt collaborate to study buffering agent for transdermal delivery in cancer models

LinKinVax signs licensing agreement with Inserm for vaccine platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...